spacer
home > ebr > winter 2018 > regional requirements
PUBLICATIONS
European Biopharmaceutical Review

Regional Requirements

Globalisation has affected the life sciences and pharmaceutical industries just as much as it has other sectors, and a growing push to standardise submission formats has opened market opportunities for many life sciences companies. The common technical document (CTD) has already become the de facto standard in many regions as more and more countries respond to the ICH’s mission of greater harmonisation around the “interpretation and application of technical guidelines and requirements for pharmaceutical product registration” (1).

Regional Regulatory Climate

Today, most countries – either directly or through regional agencies – are members of the ICH or observe its guidelines. Through ongoing consultations between ICH and regulatory agencies, most regions of the world either have adopted – or are working towards meeting – the ICH guidelines centred on the areas of quality, safety, efficacy and multidisciplinary regulatory issues.

Even though most countries and regions are still paper-based, the push towards electronic submission is growing, and more countries are adopting or at least exploring electronic CTD initiatives. However, regional differences remain, even where strong alliances and a structured approach to regulatory submissions exist.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kimty Bui-Van is head of regulatory and pharma services practice at ProductLife Group, where she is responsible for the coordination of all regulatory affairs activities undertaken on behalf of clients. She draws on nearly 20 years of experience in regulatory affairs, both within the industry and as a consultant, to guide clients through all aspects of regulatory affairs, including initial submissions, variations, renewals and product lifecycle management. Kimty has been instrumental in establishing a transformative approach to managing affiliate regulatory and pharmacovigilance activities globally on behalf of clients. 
spacer
Kimty Bui-Van
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

2019 IPEC Europe Annual Excipients Forum, Malta, 31 January

Join NSF at this dynamic conference in Malta on the 31st January 2019, recognised to be one of the key events for pharmaceutical excipients in Europe.
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 
Industry Events

10th Annual Summit for Clinical Ops Executives

18-21 February 2019, Hyatt Regency Orlando, Florida

Celebrating its 10th successful year, SCOPE Summit 2019 takes place February 18-21 in Orlando, FL. Over the course of four stimulating days of in-depth discussions in 19 different conferences, 3 plenary keynote sessions, and the ever-popular interactive breakout discussions, the programming focuses on advances and innovative solutions in all aspects of clinical trial planning, management and operations, including...
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement